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AbstrAct
Objectives To present a snapshot of experimental 
cardiovascular research with a focus on geographical and 
temporal patterns of early termination due to poor accrual.
Setting The Aggregate Analysis of  ClinicalTrials. gov 
(AACT) database, reflecting  ClinicalTrials. gov as of 27 
March 2016.
Design The AACT database was searched for all 
cardiovascular clinical trials that started from January 
2006 up to December 2015.
Results Thirteen thousand and seven hundred twenty-
nine cardiovascular trials were identified. Of these, 8900 
(65%) were classified as closed studies. Globally, 11% 
of closed trials were terminated. This proportion varied 
from 9.6% to 14% for trials recruiting from Europe and 
Americas, respectively, with a slightly decreasing trend 
(p=0.02) over the study period. The most common reason 
for trials failing to complete was poor accrual (41%). 
Intercontinental trials exhibited lower figures of poor 
accrual as the reason for their early stopping, as compared 
with trials recruiting in a single continent (28% vs 44%, 
p=0.002).
Conclusions Poor accrual significantly challenges the 
successful completion of cardiovascular clinical trials. 
Findings are suggestive of a positive effect of globalisation 
of cardiovascular clinical research on the achievement of 
enrolment goals within a reasonable time frame.
IntroductIon
Clinical trials may terminate for a variety of 
reasons, some of which correctly envisaged 
in the study protocol1 2 and others unfore-
seen and attributable to failures in the trial 
conduct. Examples of appropriate reasons 
for terminating a trial prior to completion 
include unequivocal evidence of futility or 
harm.3 In this case early stopping may prevent 
additional patient exposure to ineffective or 
harmful treatments and limit further expendi-
ture of resources on unsuccessful approaches. 
Conversely, premature termination due to 
poor accrual clearly reflects a failure of the 
trial process since trials completed with less 
than expected enrolment are usually delayed 
and unable to meet their intended objectives 
meaningfully.
Clinical trials that fail to recruit successfully 
or in a timely manner their target number 
of participants pose ethical, financial and 
statistical issues.4 They are a major concern in 
research areas where the acuity of the disease 
and the quickly evolving treatment paradigm 
render original research questions obsolete 
if not implemented in a timely manner. This 
partially explains why poor accrual and its 
consequences have been extensively inves-
tigated in some areas, mostly in oncology5–7 
and less in others.
Unsuccessful recruitment has been 
recently acknowledged8 9 as the leading factor 
in cardiovascular trial failure, generating 
resource-consuming underpowered trials 
that provide only inconclusive data with no 
or little return on investments.
The past decade has seen a fast growth 
in cardiovascular research.10 Documenting 
impact of poor accrual on early termina-
tion of cardiovascular trials, also in terms 
of geographical and temporal trends, is 
important as it can provide insights to inform 
future trials.
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Strengths and limitations of this study
 ► To identify cardiovascular clinical trials terminated 
early because of poor accrual, this study relies on 
the most updated release of the Aggregate Analysis 
of ClinicalTrials.gov database and on automated and 
replicable text mining techniques.
 ► By analysing early termination due to poor accrual 
by continent of recruitment over time, the study 
shows that poor accrual exhibits geographical 
heterogeneity with lower figures for intercontinental 
trials.
 ► In interpreting the results it must be acknowledged 
that ClinicalTrials.gov is representative of registered 
trials recruiting from Europe and Americas. On the 
contrary, it cannot be ruled out that some selection 
bias occurred for trials recruiting from Asia and 
Oceania since they are increasingly registered in 
other regional registries.
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The development of clinical trial registries, such as 
ClinicalTrials. gov, affords a remarkable opportunity to 
better understand the extent of early termination in 
cardiovascular trials. In the beginning,  ClinicalTrials. 
gov was set to increase public awareness of clinical trials, 
and its systematic evaluation was hindered by a lack of 
access to the complete, annotated data. This registry now 
serves as a mandatory repository for information on most 
clinical studies run under US regulations, and registra-
tion with  ClinicalTrials. gov is mandatory for publishing 
study results in many peer-reviewed journals. In addition, 
the database for Aggregate Analysis of  ClinicalTrials. 
gov (AACT),11 a high-quality, searchable database of 
the information contained in  ClinicalTrials. gov, is now 
publicly available.
By leveraging information available through the AACT 
database, reflecting  ClinicalTrials. gov as of 27 March 2016, 
we present a snapshot of the last 10 years of cardiovascular 
research, with a focus on geographical and temporal 
patterns of early termination due to poor accrual.
MaterIals and Methods
The AACT database, reflecting  ClinicalTrials. gov as of 
27 March 2016, is the data source. A comprehensive 
dictionary for the data elements in AACT is available 
online.12
The Medical Subject Headings (MeSH) code field in 
the AACT database was queried for at least one of the 
following MeSH codes: A07 cardiovascular system; C14 
cardiovascular diseases; D27.505.954.411 cardiovascular 
agents (including antiarrhythmia/antihypertensive/
cardiotonic/fibrinolytic/natriuretic/vasoconstrictor/
vasodilator agents, calcium/potassium/sodium channel 
blockers, cardioplegic/sclerosing solutions and nitric 
oxide donors); E01.370.370 diagnostic techniques, 
cardiovascular (including angiography, angioscopy, blood 
circulation time, blood flow velocity, blood pressure/
volume determination, capillary fragility, carotid inti-
ma-media thickness, heart function tests, laser Doppler 
flowmetry, microscopic angioscopy, plethysmography, 
pulse wave analysis and tilt-table test); E04.100 cardiovas-
cular surgical procedures (E04.100.376 cardiac surgical 
procedures, E04.100.700 reperfusion and E04.100.814 
vascular surgical procedures); G09.330 cardiovas-
cular physiological phenomena (including ventricular 
function, myocardial contraction, blood circulation, 
neovascularisation, haemodynamics and cardiovascular 
deconditioning); and H02.403.429.163 cardiology, with 
the aim to identify all studies dealing with a cardiovas-
cular condition. The final sample was limited to all such 
studies, started in the past decade — from January 2006 
to December 2015 — and classified as ‘Interventional’, 
therein referred to as cardiovascular trials.
Study characteristics that have been considered are year 
of start date, phase (available only for drug and biologics 
trials), type of intervention, number of arms, primary 
purpose, endpoint classification, intervention model, 
masking, number and location of the facilities involved, 
and number of patients enrolled.
The rate of studies that have stopped recruiting or 
enrolling participants early and will not start again, 
defined as ‘terminated’ studies, was estimated on studies 
that are no longer recruiting participants because they 
have enough participants already, have ended or have 
been stopped for some reason, and referred to as ‘closed’ 
studies. The latter definition embraces also withdrawn 
studies, intended as studies closed with no patients 
enrolled.
Termination was used as the dichotomous outcome 
variable of a conditional inference tree built to detect 
associations with the study characteristics listed above.
Study duration was calculated as the difference between 
start date and completion date, only for closed studies 
and ‘actual’ completion date type.
To establish the reason for stopping, text mining was 
applied to the narrative field of reason for study termina-
tion. The following text preprocessing procedures were 
applied in the following order: conversion to lower case, 
removing numbers, removing punctuation, removing 
stop-words, stemming words, removing stemmed uninfor-
mative terms (‘studi’, ‘clinical’, ‘trial’, ‘patient’, ‘subject’, 
‘approach’, ‘termin’, ‘stop’), treating the stemmed terms 
‘accrual’ and ‘recruit’ as synonyms of ‘enrol’, stripping 
white space and building a sequence of two adjacent 
words from the text (bigrams).
A randomly selected sample of about 10% of terminated 
trials was extracted to assess the accuracy of automated 
text mining in identifying poor accrual as compared with 
manual review (gold standard).
AACT was downloaded in pipe delimited text format 
and managed in R V.3.3.0 software. The location of each 
facility, expressed as country in the AACT database, was 
ascribed to a region and to one of the five continents 
through R packages ‘countrycode’ and ‘rworldmap’. Text 
mining was performed with ‘tm’ R package. Tree-based 
models were fit with ‘party’ R package.
results
In a 10-year time span, from 2006 to 2015, 13 729 cardio-
vascular trials were identified.
As shown in figure 1, cardiovascular trials were prev-
alently run in Northern America (41%), followed by 
Eastern and Western Europe (25%) and Eastern Asia 
(8%). The regions that together contributed to less 
than 0.5% were Middle, Eastern and Western Africa and 
Central Asia.
Single-centre studies accounted for the majority (60%) 
of cardiovascular trials. Among intercontinental trials 
(n=1089), the most likely collaborations were bilateral 
between Americas and Europe (32%), trilateral between 
Americas, Asia and Europe (14%), quadrilateral between 
Americas, Asia, Europe and Oceania (11%), and world-
wide (8%).
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Overall, the most common interventional model was 
parallel design (60%). Of studies reporting number 
of arms (n=13 419), 27% were single-armed and 57% 
had two arms. Multiarm studies (n=9735) were typically 
randomised (89%) and blinded (38% double-blinded 
and 20% single-blinded). Phase II and III trials together 
accounted for 4500 studies and 5052 recorded the phase 
as ‘not applicable’. The most frequently observed inter-
vention was drug (n=6334), followed by device (n=2736) 
and procedure (n=1405).
Eight thousand and nine hundred cardiovascular trials 
(65%) were classified as closed studies. Of these, 11% 
were terminated. The reason for termination was missing 
for 141 studies.
According to the classification tree shown in figure 2, 
termination was significantly associated with facilities’ 
location (p<0.001). In addition, the type of intervention 
had an effect on the rate of early termination (lowest 
for behavioural and dietary supplement interventions as 
compared with all other types, p<0.001) for trials run in 
Americas and multinational trials run in Americas and 
Europe or in Americas, Asia and Europe. Among trials 
run in Europe, parallel trials were more likely to termi-
nate early than trials with other intervention models 
(7.3% vs 11.7%, p=0.012).
Low figures of early termination for trials run in Asia 
and for trials recently started should be interpreted with 
caution since they may suffer from a selection bias.
The single stemmed term ‘enrol’ occurred in 404 
reasons for study termination and it was most associ-
ated with the adjectives ‘poor’, ‘low’ and ‘slow’, making 
poor accrual the most common reason for trials failing 
to complete. The second most common substantive was 
‘fund’, with 85 occurrences and it was associated with the 
term ‘lack’, followed by ‘sponsor’, with 70 occurrences, 
and associated with the term ‘decis’. Table 1 reports the 
Figure 1 Geographical distribution of the facilities involved in cardiovascular trials, 2006–2015.
Figure 2 Conditional inference tree predicting early termination. Retained variables: facility location (Americas (AM), 
Americas Europe (AM-EU), Americas Asia Europe (AM-ASIA-EU), Asia, Europe (EU), Other), year of start date, intervention type 
(behavioural (behav), biological (bio), device, dietary supplement (diet), drug, genetic (gene), procedure (proc), radiation (rad), 
other), and intervention model (crossover (Cr), factorial (Fac), parallel (paral), single group (sing)).
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most frequently used bigrams in the reason for termina-
tion field. A network graph in figure 3 shows the most 
frequent relations (ie, correlation >0.15) between the 
(stemmed) terms ‘enrol’, ‘fund’, ‘sponsor’, ‘safety’ and 
‘interim’, and the other words in the corpus of reason for 
termination text data.
On a random sample of 85 terminated trials, where 
the reason for termination was manually reviewed by 
one of the authors (IB), the prevalent reason was poor 
accrual (47%). Stopping occurred for lack of funding 
and sponsor decision in 8% and 6% of the sampled trials, 
respectively. Appropriate reasons for termination based 
on internal or external evidence of futility or lack of safety 
accounted for 26% of all reasons. The sensitivity and spec-
ificity of the stemmed term ‘enrol’ in identifying poor 
accrual were 97.5% and 100%, respectively.
Terminated trials actually involved a total of 114 609 
enrolled subjects (plus 44 513 scheduled) and more than 
10 500 facilities worldwide. Eighteen thousand and eight 
hundred eight patients and 2319 facilities actually took 
part in trials terminated because of poor accrual.
The patterns of premature termination shown in 
figure 4 varied from 9.6% to 14% (p<0.001) among the 
two most contributing continents, Europe and Amer-
icas, and were slightly decreasing over the study period 
(p=0.02).
Intercontinental trials exhibited comparable figures 
of termination and lower figures of unsuccessful accrual 
Table 1 Stemmed bigrams occurring in the reason for 




















Furthermore, the term ‘enrol’ occurred as the reason for stopping 
of 90 withdrawn trials and 18 suspended trials. Table 2 reports the 
proportion of trials terminated for poor accrual over terminated 
trials by study characteristic.
Figure 3 Network graph showing the most frequent relations (ie, correlation >0.15) between the (stemmed) terms ‘enrol’, 
‘fund’, ‘sponsor’, ‘safety’ and ‘interim’, and the other words in the corpus of reason for termination text data. Solid lines identify 
associations with a correlation >0.15 and dotted lines identify tautological associations.
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as the reason for their early stopping, as compared with 
intracontinental trials (13% vs 11%, p=0.24, termination, 
of whom 28% vs 44%, p=0.002, were due to poor accrual, 
respectively). Figure 5 shows the time trend of poor 
accrual for intercontinental trials (p value for trend=0.02, 
p value for the difference=0.001).
A median actual duration of 24 months was observed 
both on closed trials and on the subset of terminated 
trials. Only a slight difference emerged in the third 
quartile, ranging from 38 to 39 months for closed and 
terminate trials, respectively. For this reason, time trends 
were truncated at the last biennium under study.
Poor accrual accounted for more than 40% of reasons 
for early stopping in trials recruiting from Americas and 
Europe. This proportion was by far inferior for all other 
continents of recruitment, although caution must be 
taken in interpreting these figures since they rely on small 
absolute numbers (table 2).
conclusIon
Clinical trials are a key step in advancing new therapeutic 
concepts for the management of chronic cardiovascular 
diseases from the research setting to the clinical practice.13 
Despite this achievement, the successful recruitment of 
the targeted number of participants in a given time frame 
remains a significant challenge to clinical trials.14 Delayed 
and abandoned trials represent a waste of scarce human 
and economic resources, which may slow the advance-
ment of medical progress or reduce its timely impact on 
patient health and well-being.
Therefore, a thorough understanding of the nature of 
trial enrolment patterns, from an overview on aggregate 
data through to the working of individual trials, is of para-
mount importance.
This study contributes to a growing body of research on 
early termination due to poor accrual in cardiovascular 
trials,2 3 9 providing further insights into geographical and 
temporal patterns.
Among study findings, about 11% of all closed trials 
were terminated, which is consistent with other cross-sec-
tional studies using the  ClinicalTrials. gov registry.9 15 
When restricted to phase II and phase III trials together, 
the proportion of early termination (14%) was slightly 
inferior to that reported on a recent study4 based on the 
National Library of Medicine clinical trial registry (19%).
Consistent with existing literature,8 9 the most common 
reason for cardiovascular trials failing to complete was 
poor accrual (41%). Common logistical reasons were 
related to lack of funds and sponsor decision. Since 
reason for termination was automatically characterised by 
word patterns through text mining, we may just specu-
late that the concepts underlying ‘safety concerns’, ‘safety 
issue’ and ‘interim analysis’ pertain to appropriate termi-
nation, possibly on data safety and monitoring board 
advice, because of excessive toxicity or in accord with 
early stopping rules.
Almost all trials are dependent on the willingness of 
patients and professionals to give their time and effort to 
participate, and we estimated that the human dimension 
of poor accrual involved more than 8000 patients and the 
staff of 2000 sites.
The overall patterns of early termination and those 
concerned with poor accrual exhibited geographical vari-
ations. Cardiovascular trials recruiting in the two most 
contributing continents exhibited the highest and lowest 
proportion of early termination due to unsuccessful 
accrual in Americas and Europe, respectively, across all 
the study period.
Nevertheless, time trends should be interpreted with 
caution, since the decrease seen in the last biennium of 
the evaluation may be an artefact, reflecting both a delay 
in updating trial status in  ClinicalTrials. gov and a selec-
tion of trials with a short duration and less likely to suffer 
Figure 4 Proportion of early terminations by continents of 
recruitment over time. Cardiovascular trials, 2006–2015.
Figure 5 Proportion of early terminations due to poor 
accrual for trials recruiting from a single continent or from 
different continents over time. Cardiovascular trials, 2006–
2015.
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Table 2 Characteristics of closed cardiovascular interventional trials – 2005–2015: proportion of terminated trials (% 
terminated) and proportion of trials terminated because of lack of accrual (% poor) by study characteristics
N % Terminated p Value‡ % Poor p Value‡
Year 2006–2007 1078 7.0 <0.001 42.3 <0.001
2008–2009 1893 6.6 43.0
2010–2011 1955 6.0 43.3
2012–2013 1596 4.9 32.8
2014–2015 624 4.2 44.2
Facility 
location*
Africa 32 3.2 <0.001 100.0 <0.001
Americas 3769 14.0 46.3
Americas Asia Europe 129 13.2 17.6
Americas Asia Europe Oceania 89 7.9 14.3
Americas Europe 256 18.0 34.7
Asia 1079 5.6 33.3
Europe 2454 9.6 40.4
Oceania 71 18.3 30.8
Other 374 4.2 50.8
Missing 647 5.9 23.7
Phase Phase 0 81 9.9 <0.001 32.9 0.012
Phase 1 736 11.3 29.8
Phase 1/Phase 2 415 15.1 36.5
Phase 2 1542 11.7 44.4
Phase 2/Phase 3 231 13.2 36.9
Phase 3 1419 11.0 51.5
Phase 4 2997 8.2 46.6
NA 1479 8.6 14.3
Intervention 
type
Behavioural 603 4.5 <0.001 1.8 <0.001
Biological 294 10.2 33.3
Device 1679 11.9 42.7
Dietary supplement 266 5.3 50.0
Drug 4309 13.4 39.8
Genetic 26 7.7 0.0
Procedure 44 13.6 45.1
Radiation 784 10.5 83.3
Other 895 5.4 47.9
No of arms 1 2474 11.2 0.004 42.0 <0.001
2 4725 11.7 43.5
>2 1466 8.5 29.8
Missing 235 13.6 34.4
Primary 
purpose
Basic science 250 4.8 <0.001 25.0 0.002
Diagnostic 491 11.0 50.0
Health services research 197 4.1 37.5
Prevention 1008 9.5 37.5
Screening 46 4.3 0.0
Supportive care 280 10.3 75.0
Continued
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N % Terminated p Value‡ % Poor p Value‡
Treatment 6264 12.1 39.7
Missing 364 8.0 48.3
Allocation Non-randomised 1052 11.0 0.986 31.0 0.155
Randomised 6039 11.0 41.9
Missing 1809 11.2 44.1
Endpoint 
classification
Bioavailability 18 5.6 <0.001 0.0 0.155
Bioequivalence 38 7.9 66.7
Efficacy 2668 10.7 47.2
Pharmacodynamics 121 11.6 35.7
Pharmacokinetics 124 4.0 0.0
Pharmacokinetics/Dynamics 111 12.6 28.6
Safety 625 9.1 36.8
Safety/Efficacy 3811 12.8 37.2
Missing 1384 8.5 47.5
Masking Double-blind 2775 12.6 <0.001 36.7 0.119
Open-label 4798 11.2 43.1
Single-blind 1287 7.1 46.2
Missing 40 15.0 33.3
Intervention 
model
Crossover 713 7.4 0.009 39.6 0.148
Factorial 156 8.3 38.5
Parallel 5246 11.4 41.5
Single group 2727 11.4 40.8
Missing 58 15.5 33.3
No of enrolled (0, 100] 5521 14.0 <0.001 45.3 <0.001
(100, 1000] 2832 6.3 27.4
(1000, 20 000] 467 5.6 10.7
>20 000 53 3.8 0.0
Missing 27 19.2 40.0
No of facilities 
(per study)
1 4934 10.3 <0.001 44.4 <0.001
(1, 10] 1876 14.4 44.1
(10, 50] 1047 11.5 35.0
(50, 100] 204 14.2 17.2
>100 191 9.4 16.7




1 6703 11.8 0.068 41.3 0.228
2 1584 8.2 44.0
>2 613 13.8 32.9
Conditions† Acute coronary syndrome 205 12.2 - 48.3 -
Atrial fibrillation 380 13.4 37.2
Cardiovascular diseases 481 5.4 34.6
Coronary artery disease 609 8.7 50.9
Table 2 Continued 
Continued
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from low accrual. However, comparisons between conti-
nents of recruitment per year appear to be appropriate 
and reliable.
It is interesting to notice that intercontinental trials, 
particularly those in bilateral collaboration with Americas 
and Europe, suffer more from early termination and less 
from termination due to lack of accrual, as compared with 
studies completely run in only one of the participating 
continents. Clearly, intercontinental trials are often 
resource-intensive, large-scale randomised controlled 
clinical trials, recruiting thousands of patients from large 
numbers of trial sites (ie, megatrials).
On the one hand, this probably allows to recognise 
the achievement of enrolment goals within a reasonable 
time frame as one of the numerous advantages of global-
isation of cardiovascular clinical trials, often evolving 
into megatrials,16 but on the other hand it highlights 
that other organisational and financial issues challenge 
this process. Intercontinental trials represent a valuable 
attempt to harmonise the generation of clinical evidence 
across continents. Their implementation is particularly 
promising in device trials,17 where the comparison of 
procedural outcomes, using similar devices in different 
environments, makes it possible to disentangle the effects 
of practice patterns and procedural technique on clinical 
results.
Some study limitations must be acknowledged. First 
is the generalisability of study results. A recent inves-
tigation18 on trends in global clinical trial registration 
from 2005 to 2013, based on International Clinical Trials 
Registry Platform data, reports that  trials conducted in 
Northern America and Latin America and Caribbean 
were almost exclusively registered in  ClinicalTrials. gov. 
Also European trials were predominantly registered in 
ClinicalTrials. gov rather than in the EU Clinical Trials 
Register. Conversely, trials conducted in Oceania and Asia 
were increasingly registered in other regional registries 
such as the Australian New Zealand Clinical Trials Registry 
and the Japan Primary Registries Network, respectively.
As a consequence, study results concerning Europe and 
Americas can be regarded as representative of all regis-
tered trials recruiting from these continents. Moreover, 
differences in the extent of early termination and of poor 
accrual can be interpreted as genuine. On the contrary, 
it cannot be ruled out that some selection bias occurred 
for trials recruiting from Asia and Oceania. Therefore, 
the extent of early termination for trials run in these two 
continents may be underestimated.
Furthermore, the identification of trials terminated 
for poor accrual relied on an automated process with an 
estimated sensitivity of 97.5%; thus, the extent of poor 
accrual may be underestimated.
Poor accrual is a significant barrier to the successful and 
timely completion of clinical trials and to the advance-
ment of medical knowledge. Although this issue may 
be addressed in a variety of ways, a global collaborative 
perspective on the planning and conduct of some cardio-
vascular clinical trials should be further encouraged.19
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N % Terminated p Value‡ % Poor p Value‡
Coronary disease 341 10.0 32.3
Heart failure 644 13.8 53.9
Hypertension 901 10.2 29.3
Multiple myeloma 620 15.8 42.9
Myocardial infarction 216 9.7 38.2
Myocardial ischaemia 414 10.9 20.0
Stroke 477 10.9 34.6
Overall 8900 11.1 41.1
*Facility location describes the study-level location of enrolling sites. It results in a single continent for single-centre trials and multicentre 
multinational trials and in a combination of continents for intercontinental trials.
†The number of MeSH conditions sums to 13 501 across the 8900 closed trials. Only the conditions exceeding an absolute frequency of 200 
are listed.
‡χ2 or Fisher test p values.
Table 2 Continued 
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